MGUS can cause eye problems, though it does so uncommonly enough that many hematologists and patients think of the condition as entirely harmless. A growing body of case reports and small studies has documented a range of ocular complications linked to the abnormal proteins produced in MGUS, from crystal deposits in the cornea to fluid accumulation under the retina. In some cases, the eye problem is actually the first clue that a monoclonal gammopathy exists at all. The connection is rare but real, and understanding it matters if you have been diagnosed with MGUS and notice changes in your vision.
Why “Undetermined Significance” Does Not Always Mean “No Significance”
MGUS is defined by the presence of an abnormal protein (a monoclonal immunoglobulin, or “M-protein”) in the blood at low levels, without evidence of a full-blown cancer like multiple myeloma or lymphoma. The word “undetermined” in the name reflects the fact that, for most people, this protein never causes organ damage. But researchers have increasingly recognized that the M-protein itself, or antibodies the abnormal clone produces, can sometimes injure tissues directly. The eyes are one of those tissues.
This realization led specialists to propose a more specific label: monoclonal gammopathy of ocular significance, or MGOS. The term applies when a patient has MGUS by standard blood-test criteria but also has eye disease caused by the monoclonal protein, even though they are otherwise healthy. Researchers have argued that the MGOS label is necessary to distinguish these patients from those whose MGUS truly causes no symptoms and from those whose eye problems stem from more advanced blood cancers like myeloma.
Corneal Crystal Deposits
The most well-documented eye problem in MGUS is paraproteinemic keratopathy, a condition in which the abnormal immunoglobulin deposits as crystals inside the cornea. These corneal deposits can appear in various layers of the cornea and consist predominantly of immunoglobulins, most often the IgG type. Under an electron microscope, the crystals typically form parallel band-shaped structures. The prevailing explanation is that the cornea’s normal cleanup cells cannot keep pace with the overproduced monoclonal protein, so the excess accumulates in the tissue between cells and triggers cell death in the surrounding corneal cells.
For patients, the practical effect ranges from no symptoms at all to a noticeable decline in vision. In mild cases, an ophthalmologist may spot the deposits during a routine slit-lamp exam before you notice anything wrong. In more severe cases, the deposits scatter light enough to blur your sight. Crystalline keratopathy is one of those findings that can actually lead to the diagnosis of a monoclonal gammopathy in the first place, because the corneal appearance is distinctive enough to prompt blood testing.
A separate corneal condition called hypercupremic keratopathy has also been reported. In this variant, the monoclonal immunoglobulin has an unusual tendency to bind copper, and the copper-laden protein deposits in the cornea in a pattern that can resemble the rings seen in Wilson disease. Both crystalline keratopathy and hypercupremic keratopathy fall under a broader umbrella of uncommon physicochemical alterations of the monoclonal immunoglobulin that favor crystallization or exaggerated copper binding.
What Happens When the Cornea Is Treated
Because corneal deposits can impair vision, some patients eventually need a corneal transplant. But here is where the story gets frustrating: the deposits can come back after transplantation, because the underlying source of the abnormal protein, the clone of plasma cells in the bone marrow, is still active. A case report documented exactly this recurrence, noting that the return of deposits in the new cornea reinforced the idea that patients with vision-impairing keratopathy from MGUS truly have a monoclonal gammopathy of ocular significance, not a benign condition that can be dismissed.
This recurrence pattern has practical implications. If you need corneal surgery for paraproteinemic keratopathy, your ophthalmologist and hematologist may need to discuss whether treatment directed at the underlying plasma cell clone could help protect the graft. That kind of cross-specialty coordination is still uncommon, partly because MGOS itself is so rare, but awareness is growing.
Misdiagnosis as Inherited Corneal Dystrophy
One under-appreciated risk is that paraproteinemic keratopathy can look very similar to certain inherited corneal dystrophies under the slit lamp. A study of twelve patients with paraproteinemic keratopathy found that three of them had initially been diagnosed with an inherited corneal dystrophy, either lattice dystrophy or Thiel-Behnke dystrophy. Genetic testing of those three patients for the TGFBI gene, the gene responsible for the most common inherited corneal dystrophies, came back negative, confirming that their deposits were not genetic in origin.
This matters because the treatment paths diverge sharply. An inherited dystrophy is managed with local eye procedures, while paraproteinemic keratopathy may ultimately require treatment aimed at the blood disorder. If you have been told you have a corneal dystrophy but the pattern does not fit neatly, or if corneal deposits recur after a transplant, asking about monoclonal gammopathy testing is reasonable.
Macular and Retinal Problems
The cornea gets the most attention, but the retina can also be affected. A study of MGUS patients identified a pattern of neurosensory macular detachment, meaning fluid collecting under the central retina, with no obvious leakage visible on fluorescein angiography. Four patients (seven eyes) showed this pattern, all with IgG-type MGUS. The fluid was accompanied by vitelliform (egg-yolk-like) material and proved stubbornly resistant to every standard treatment attempted, including anti-VEGF injections, photodynamic therapy, and oral medications like eplerenone and acetazolamide.
This treatment resistance is a red flag worth knowing about. If you have MGUS and develop unexplained fluid under the macula that does not respond to the usual therapies, the monoclonal protein itself may be the culprit. Researchers have also noted that patients who already have an underlying chorioretinal condition seem more likely to develop this kind of fluid accumulation, suggesting the M-protein may worsen pre-existing vulnerabilities in the retina.
A separate and rarer retinal complication is autoimmune retinopathy. In this scenario, the monoclonal clone produces antibodies that target proteins in the retina’s light-sensing cells (photoreceptors). Anti-retinal autoantibodies have been identified in MGUS patients, and the resulting dysfunction can affect how well the photoreceptors work. This is a different mechanism from the fluid accumulation described above and represents an immune-mediated attack rather than a protein-deposition problem.
Hyperviscosity and the Retina
MGUS itself does not typically raise blood viscosity enough to cause retinal problems, but it is worth understanding the spectrum because MGUS can progress to conditions that do. Waldenström macroglobulinemia and aggressive multiple myeloma can thicken the blood to the point where retinal veins become engorged and hemorrhage. The clinical picture of hyperviscosity retinopathy includes dilated, tortuous retinal veins, widespread retinal hemorrhages, disc swelling, cotton-wool spots, and fluid under the retina.
A case report of hyperviscosity retinopathy in Waldenström macroglobulinemia described serous macular detachment that was “angiographically silent,” meaning it did not show leakage on standard imaging, and that proved difficult to treat even with six months of combined systemic and local therapy. In another case of aggressive myeloma, the retinal appearance mimicked a bilateral central retinal vein occlusion.
The relevance to MGUS patients is indirect but important: if you have MGUS and suddenly develop floaters, blurred vision, or dark spots in your visual field, these symptoms deserve urgent evaluation. Although full hyperviscosity retinopathy is not expected in MGUS alone, a sudden change in vision could signal that the disease has progressed.
Amyloid Deposits in and Around the Eye
Amyloidosis is a condition in which misfolded proteins accumulate as waxy deposits in tissues. In the immunoglobulin light-chain form (AL amyloidosis), the deposited protein originates from the same type of plasma cell clone that produces the M-protein in MGUS. Although full-blown AL amyloidosis is a distinct and more serious diagnosis, amyloid deposits can show up in the eyelids, the conjunctiva (the thin membrane over the white of the eye), and the orbit (the bony socket). Analysis of these deposits has confirmed that immunoglobulin light chain, either kappa or lambda type, is the predominant protein found in them.
Eyelid or orbital amyloid can cause visible lumps, drooping of the eyelid, or a gritty sensation. Conjunctival amyloid sometimes appears as a waxy or yellowish thickening on the surface of the eye. These findings are uncommon, but when an ophthalmologist spots amyloid in the eye region, it typically triggers blood and urine tests to look for a monoclonal gammopathy and to determine whether systemic amyloidosis is present.
Dry Eye, Cataracts, and Everyday Vision Quality
Beyond the rare and dramatic complications, a study comparing 80 patients with monoclonal gammopathy to age-matched controls found that more common, everyday eye problems were also significantly more frequent. Dry eye disease was present in about 40% of the gammopathy group. Cataracts were found in roughly 17% of eyes overall, but among a subgroup of eight patients with MGUS who had not been treated with corticosteroids, cataracts appeared in nearly 78% of eyes, and posterior cortical cataracts, a less common subtype, appeared in about 22% of eyes. Ocular surface disease, posterior cortical cataracts, and cataracts in general were all significantly more common in the gammopathy patients than in the control group.
The same study found that best-corrected visual acuity and ocular surface disease index scores were significantly worse in the gammopathy group. In plain terms, patients with monoclonal gammopathy had measurably poorer vision and more eye-surface discomfort than people of the same age without the condition. The researchers also identified potential corneal immunoglobulin deposition in about 4% of the gammopathy patients.
These findings are a useful counterweight to the narrative that MGUS is purely a blood-test curiosity. Even if the rare complications like crystalline keratopathy never develop, you may still have a higher-than-expected burden of dry eye and cataracts. These are treatable conditions, but they need to be caught.
What to Actually Watch For
If you have MGUS, knowing which eye symptoms to take seriously can help you catch problems early. The symptoms fall into a few practical buckets:
- Gradual blurring: A slow decline in vision clarity, especially if it does not correct fully with glasses, could point to corneal deposits or cataract development. This is worth mentioning at your next eye appointment even if it seems minor.
- Persistent dryness or grittiness: Dry eye disease is common in the general population, but it appears to be more common with monoclonal gammopathy. If over-the-counter drops are not helping, an ophthalmologist can evaluate whether something beyond ordinary dry eye is going on.
- Central vision distortion: If straight lines start to look wavy or a dark spot appears in the center of your visual field, that could indicate macular fluid accumulation. This warrants prompt evaluation, not a wait-and-see approach.
- Sudden vision loss or floaters: A sudden shower of floaters, flashing lights, or a curtain-like shadow across your vision requires urgent attention. While these symptoms have many possible causes, in someone with MGUS they could signal retinal complications or, in a worst-case scenario, progression of the underlying blood disorder.
- Eyelid lumps or surface changes: New lumps on the eyelid or a thickened, waxy patch on the surface of the eye should be examined. Amyloid deposition is rare but diagnosable with a biopsy.
The Case for Regular Eye Exams
Given all of this, researchers who have studied ocular involvement in monoclonal gammopathy have recommended that these patients receive a yearly ophthalmic checkup. The logic is straightforward: some of these eye complications develop silently before the patient notices a change, and early detection improves outcomes. An ophthalmologist looking specifically for corneal deposits, signs of macular fluid, and ocular surface disease can catch problems that you would not feel in their earliest stages.
This recommendation comes from the same study that documented the higher rates of dry eye, cataracts, and worse visual acuity in gammopathy patients. The researchers concluded that regular screening could improve quality of life in this group. Whether every hematologist currently tells MGUS patients to get yearly eye exams is another question; the evidence supporting the practice is there, but awareness among non-ophthalmologists is still catching up.
When Eye Findings Lead to the Diagnosis
One of the more striking aspects of the MGUS-eye connection is that the relationship sometimes runs in reverse: an ophthalmologist finds something unusual in the eye, orders bloodwork, and discovers the monoclonal gammopathy for the first time. Crystalline keratopathy, unexplained macular detachment, or amyloid deposits in the orbit can all serve as the initial diagnostic clue. A review of the uncommon forms of ocular injury accompanying monoclonal gammopathy noted that these ocular findings “may lead, also, to the diagnosis of monoclonal gammopathy.”
For people who do not yet have a diagnosis of MGUS, this means that an eye exam could be the entry point into identifying a blood condition. Ophthalmologists who are aware of the association are better positioned to order the right blood tests when they see deposits or fluid patterns that do not fit the usual explanations. This is one of the stronger arguments for classifying MGOS as its own entity: it signals to clinicians that the eyes are not just passive bystanders in monoclonal gammopathy but can be the first affected organ.
How Treatment Works Across Specialties
Managing eye problems from MGUS almost always requires coordination between at least two specialists: a hematologist monitoring the blood disorder and an ophthalmologist treating the eye. The challenge is that standard ophthalmic treatments often fall short when the underlying cause is a circulating monoclonal protein. As the maculopathy study showed, anti-VEGF injections and photodynamic therapy, which work well for other causes of macular fluid, did not resolve the subretinal fluid in MGUS patients. Similarly, corneal transplants can fail if the plasma cell clone keeps producing the protein that caused the deposits in the first place.
In some cases, hematologists may consider clone-directed therapy, meaning drugs that target the abnormal plasma cells, even though the patient does not meet the traditional criteria for myeloma treatment. This is a relatively new and evolving area. The threshold for treating the blood disorder is generally set by the severity of the eye damage and whether it is progressing. There are no large clinical trials guiding these decisions yet, so treatment tends to be individualized, often drawing on the experience of centers that have seen multiple MGOS cases.
For the more common problems like dry eye and cataracts, standard ophthalmologic care applies. Artificial tears, punctal plugs for severe dry eye, and cataract surgery all remain appropriate. The key difference is that the treating ophthalmologist should be aware of the underlying gammopathy, because it may influence surgical planning or raise the index of suspicion if unusual deposits are found during surgery.